Top

Hepatology International

Published in:

01-06-2008 | NASH (NAFLD), PHT, Hepatic Failure and Others

Comparative redox status in alcoholic liver disease and nonalcoholic fatty liver disease

Authors: Payal Bhardwaj, Kaushal Madan, Sandeep Thareja, Yogendra Kumar Joshi, Anoop Saraya

Published in: Hepatology International | Issue 2/2008

Abstract

Purpose

Altered redox status has been implicated in pathogenesis of alcoholic liver disease (ALD) as well as in nonalcoholic fatty liver disease (NAFLD). This study was planned to find the relative role of redox status in these two diseases.

Methods

A total of 44 patients with ALD and 32 patients with NAFLD and 25 apparently healthy controls were included in the study. Redox status was estimated by measuring oxidative stress (superoxide dismutase (SOD) and lipid peroxidation products as thiobarbituric acid reactive substances (TBARS)) and antioxidant status (ferric reducing ability of plasma (FRAP) and vitamin C).

Results

TBARS level was raised significantly in both ALD (3.5 (2.3–9.4) vs. 1.8 (0.5–4.1) nmol/ml; P = 0.0001) and NAFLD (5.1 (1–10.2) vs. 1.82 (0.51–4.1) nmol/ml; P = 0.0001) as compared with controls, but was not different between ALD and NAFLD. SOD was significantly higher in ALD as compared to NAFLD (2.4 (1.3–7.8) vs. 0.68 (0.05–19.1) U/ml; P = 0.0001) and controls (1.12 (0.01–3.5) U/ml; P = 0.001). FRAP was lower in ALD as compared with NAFLD (345.4 (56–615.9) vs. 434.1 (197.6–733.3) μmol of Fe⁺² liberated; P = 0.001) but similar to that of controls (340.9 (141.5–697.5) μmol of Fe⁺² liberated).

Conclusions

ALD patients have a higher degree of redox imbalance as compared with NAFLD patients

Sugimoto M, Sadamoto T, Nonaka H. Clinical and pathological differences between alcoholic hepatitis and non-alcoholic steatohepatitis. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2003;38(1):34–45.PubMed

Nakano M, Fukusato T. Histological study on comparison between NASH and ALD. Hepatol Res. 2005;33(2):110–5.PubMedCrossRef

Nakano M. Histological study on the resemblance and difference between non-alcoholic steatohepatitis (NASH) and alcoholic liver diseases (ALD). Alcohol Clin Exp Res. 2005;29(Suppl 12):230S–5S.PubMed

Halliwell B. Oxidants and human disease: some new concepts. FASEB J. 1987;1(5):358–64.PubMed

Arteel GE. Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology. 2003;124:778–90.PubMedCrossRef

Masalkar PD, Abhang SA. Oxidative stress and antioxidant status in patients with alcoholic liver disease. Clin Chim Acta. 2005;355(1–2):61–5.PubMedCrossRef

Hirnwich HE, Nahum LH, Pakieten N, Fazekas JF, Bots DU. Effects of alcohol on metabolism. Am J Physiol. 1982;101:57–68.

Morimotto M, Hagbjork AI, Nariji AA. Role of cytochrome P450 2E1 in alcoholic liver disease pathogenesis. Free Rad Biol Med. 1992;10:459–64.

Seki S, Kitada T, Sakaguchi H. Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatol Res. 2005;33(2):132–4.PubMedCrossRef

10.

Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M. Oxidative stress and enzymatic status in patients with nonalcoholic steatohepatitis. Ann Clin Lab Sci. 2004;34:57–62.PubMed

11.

Perlemuter G, Davit-Spraul A, Cosson C, Conti M, Bigorgne A, Paradis V, et al. Increase in liver antioxidant enzyme activity in non-alcoholic fatty liver disease. Liver Int. 2005;25(5):946–53.PubMedCrossRef

12.

Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Non-alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183–92.PubMedCrossRef

13.

Madan K, Bhardwaj P, Thareja S, Dattagupta S, Saraya A. Oxidant stress and antioxidant status among patients with non-alcoholic fatty liver disease (NAFLD). J Clin Gastroenterol. 2006;40(10):930–5.PubMedCrossRef

14.

Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with non alcoholic steatohepaitis. Am J Gastroenterol. 2003;98:2485–90.PubMedCrossRef

15.

Yang SQ, Zhu H, Li Y, et al. Mitochondrial adaptations to obesity related oxidant stress. Arch Biochem Biophys. 2000;378:259–68.PubMedCrossRef

16.

Letteron P, Fromenty B, Terris B, et al. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol. 1996;24:200–8.PubMedCrossRef

17.

Belch JJF, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Brit Heart J. 1991;65:215–8.CrossRef

18.

Marklund S, Marklund G. Involvement of superoxide anion radical in the autooxidation of pyragallol and a convenient assay for SOD. Eur J Biochem. 1974;47:469–74.PubMedCrossRef

19.

Okamura M. An improved method for determination of l-ascorbic acid and l-dehydroascorbic acid in blood plasma. Clin Chem Acta. 1980;103:259–68.CrossRef

20.

Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of “Antioxidant Power”: the FRAP assay. Anal Biochem. 1996;239:70–6.PubMedCrossRef

21.

Lieber CS. Metabolism and metabolic effects of alcohol. Med Clin North Am. 1984;68(1):3–31.PubMed

22.

Nordmann R, Ribiere C, Rouach H. Implication of free radical mechanisms in ethanol induced cellular injury. Free Rad Biol Med. 1992;12:219–40.PubMedCrossRef

23.

Zima T, Kalousova M. Oxidative stress and signal transduction pathways in alcoholic liver disease. Alcohol Clin Exp Res. 2005;29(Suppl 11):110S–15S.PubMedCrossRef

24.

Chitturi S, George J. Interaction of iron, insulin resistance and non-alcoholic steatohepatitis. Curr Gastroenterol Rep. 2003;5(1):18–25.PubMedCrossRef

25.

Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol. 2001;281(5):G1135–9.PubMed

26.

Kojima H, Sakurai S, Uemura M, Takekawa T, Morimoto H, et al. Difference and similarity between non-alcoholic steatohepatitis and alcoholic liver diseases. Alcohol Clin Exp Res. 2005;29(Suppl 12):259S–63S.PubMed

27.

Suematsu T, Matsumura T, Sato N, Miyamoto T, Ooka T, Kamada T, et al. Lipid peroxidation in alcoholic liver disease in humans. Alcohol Clin Exp Res. 1981;5(3):427–30.PubMedCrossRef

28.

Vincent HK, Taylor AG. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond). 2006;30(3):400–18.CrossRef

29.

Couillard C, Ruel G, Archer WR, Pomerleau S, Bergeron J, Couture P, et al. Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J Clin Endocrinol Metab. 2005;90(12):6454–9.PubMedCrossRef

30.

Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol. 2005;42(6):928–40.PubMedCrossRef

31.

Kovacs P, Stumvoll M. Fatty acids and insulin resistance in muscle and liver. Best Pract Res Clin Endocrinol Metab. 2005;19(4):625–35.PubMedCrossRef

32.

Letteron P, Sutton A, Mansouri A, Fromenty B, Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology. 2003;38(1):133–40.PubMedCrossRef

33.

Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6(1):1–28.PubMedCrossRef

34.

Moriel P, Plavnik FL, Zanella MT, Bertolami MC, Abdalla DS. Lipid peroxidation and antioxidants in hyperlipidemia and hypertension. Biol Res. 2000;33(2):105–12.PubMedCrossRef

35.

Szuster-Ciesielska A, Daniluk J, Kandefer-Szerszen M. Alcohol-related cirrhosis with pancreatitis. The role of oxidative stress in the progression of the disease. Arch Immunol Ther Exp (Warsz). 2001;49(2):139–46.

36.

Kubota S, Sato N, Matsumura T, Kamada T. Chemiluminescence and superoxide dismutase in the plasma in patients with alcoholic and non-alcoholic liver injuries. Alchol. 1985;2(3):469–72.CrossRef

37.

Koch OR, De Leo ME, Borrello S, Palombini G, Galeotti T. Ethanol treatment up-regulates the expression of mitochondrial manganese superoxide dismutase in rat liver. Biochem Biophys Res Commun. 1994;201(3):1356–65.PubMedCrossRef

38.

Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quinones L, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci. 2004;106:261–268.PubMedCrossRef

39.

Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M. Oxidative stress and enzymatic status in patients with nonalcoholic steatohepatitis. Ann Clin Lab Sci. 2004;34:57–62.PubMed

40.

MacLean PD, Drake EC, Ross L, Barclay C. Bilirubin as an antioxidant in micelles and lipid bilayers: its contribution to the total antioxidant capacity of human blood plasma. Free Radic Biol Med. 2007;43(4):600–9.PubMedCrossRef

41.

Hagymási K, Blázovics A, Lengyel G, Kocsis I, Fehér J. Oxidative damage in alcoholic liver disease. Eur J Gastroenterol Hepatol. 2001;13(1):49–53.PubMedCrossRef

42.

Abuja PM. Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett. 1999;446:305–8.PubMedCrossRef

43.

Pan WH, Flegal KM, Chang HY, Yeh WT, Yeh CJ, Lee WC. Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. Am J Clin Nutr. 2004;79:31–39.PubMed

44.

Ogura T, Matsuura K, Matsumoto Y, Mimura Y, Kishida M, Otsuka F, et al. Recent trends of hyperuricemia and obesity in Japanese male adolescents, 1991 through 2002. Metabolism. 2004;53:448–53.PubMedCrossRef

45.

Notas G, Miliaraki N, Kampa M, Dimoulios F, Matrella E, Hatzidakis A, et al. Patients with primary biliary cirrhosis have increased serum total antioxidant capacity measured with the crocin bleaching assay. World J Gastroenterol. 2005;11(27):4194–8.PubMed

46.

Cao G, Booth SL, Sadowski JA, Prior RL. Increases in human plasma antioxidant capacity after consumption of controlled diets high in fruit and vegetables. Am J Clin Nutr. 1998;68(5):1081–7.PubMed

Title: Comparative redox status in alcoholic liver disease and nonalcoholic fatty liver disease
Authors: Payal Bhardwaj
Kaushal Madan
Sandeep Thareja
Yogendra Kumar Joshi
Anoop Saraya
Publication date: 01-06-2008
Publisher: Springer-Verlag
Published in: Hepatology International / Issue 2/2008
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-008-9060-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Comparative redox status in alcoholic liver disease and nonalcoholic fatty liver disease

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2008

Advanced hepatic fibrosis and cirrhosis due to nonalcoholic fatty liver disease in Sri Lankan children: a preliminary report

Clinical impact of serum transforming growth factor-alpha mRNA as a predictive biomarker for the prognosis of fulminant hepatitis

Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues

Hepatitis B reactivation after chemotherapy: two decades of clinical research

Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure

A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH)

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page